Castle Biosciences DEF 14A Filing Details Executive Compensation

Ticker: CSTL · Form: DEF 14A · Filed: 2025-04-09T00:00:00.000Z

Sentiment: neutral

Topics: proxy-statement, executive-compensation, corporate-governance

TL;DR

Castle Biosciences dropped its DEF 14A, showing exec comp details for FY24. Check it out.

AI Summary

Castle Biosciences Inc. filed its DEF 14A on April 9, 2025, for the fiscal year ending December 31, 2024. The filing details executive compensation and other corporate governance matters. Key financial data for the fiscal years 2020 through 2024 are included, with specific focus on compensation-related metrics for 2024.

Why It Matters

This filing provides shareholders with crucial information regarding how executive compensation is structured and approved, impacting corporate governance and investor confidence.

Risk Assessment

Risk Level: low — This is a routine annual filing (DEF 14A) that details executive compensation and corporate governance, not a filing indicating significant new risks or events.

Key Numbers

Key Players & Entities

FAQ

What is the primary purpose of a DEF 14A filing?

A DEF 14A filing, also known as a Definitive Proxy Statement, is filed by a company to solicit proxies from shareholders for an upcoming annual or special meeting of security holders. It provides detailed information about matters to be voted on, including director elections, executive compensation, and other corporate governance issues.

When was this DEF 14A filing submitted by Castle Biosciences Inc.?

Castle Biosciences Inc. filed this DEF 14A on April 9, 2025.

What fiscal year does this filing primarily cover regarding compensation data?

This filing primarily covers the fiscal year ending December 31, 2024, for compensation-related data.

What is the SIC code for Castle Biosciences Inc.?

The Standard Industrial Classification (SIC) code for Castle Biosciences Inc. is 8071, which falls under SERVICES-MEDICAL LABORATORIES.

Where is Castle Biosciences Inc. headquartered?

Castle Biosciences Inc. is headquartered at 505 S FRIENDSWOOD DRIVE, SUITE 401, FRIENDSWOOD, TX 77546.

From the Filing

0001447362-25-000054.txt : 20250409 0001447362-25-000054.hdr.sgml : 20250409 20250409114358 ACCESSION NUMBER: 0001447362-25-000054 CONFORMED SUBMISSION TYPE: DEF 14A PUBLIC DOCUMENT COUNT: 58 CONFORMED PERIOD OF REPORT: 20250522 FILED AS OF DATE: 20250409 DATE AS OF CHANGE: 20250409 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CASTLE BIOSCIENCES INC CENTRAL INDEX KEY: 0001447362 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services EIN: 770701774 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DEF 14A SEC ACT: 1934 Act SEC FILE NUMBER: 001-38984 FILM NUMBER: 25824341 BUSINESS ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 BUSINESS PHONE: 866-788-9007 MAIL ADDRESS: STREET 1: 505 S FRIENDSWOOD DRIVE STREET 2: SUITE 401 CITY: FRIENDSWOOD STATE: TX ZIP: 77546 DEF 14A 1 cstl-20250407.htm DEF 14A cstl-20250407 DEF 14A false 0001447362 iso4217:USD 0001447362 2024-01-01 2024-12-31 0001447362 2023-01-01 2023-12-31 0001447362 2022-01-01 2022-12-31 0001447362 2021-01-01 2021-12-31 0001447362 2020-01-01 2020-12-31 0001447362 cstl:AggregateGrantDateFairValueOfStockAwardAmountsReportedInSummaryCompensationTableMember ecd:PeoMember 2024-01-01 2024-12-31 0001447362 cstl:AggregateGrantDateFairValueOfOptionAwardAmountsReportedInSummaryCompensationTableMember ecd:PeoMember 2024-01-01 2024-12-31 0001447362 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:PeoMember 2024-01-01 2024-12-31 0001447362 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:PeoMember 2024-01-01 2024-12-31 0001447362 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:PeoMember 2024-01-01 2024-12-31 0001447362 cstl:AggregateGrantDateFairValueOfStockAwardAmountsReportedInSummaryCompensationTableMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001447362 cstl:AggregateGrantDateFairValueOfOptionAwardAmountsReportedInSummaryCompensationTableMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001447362 ecd:ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001447362 ecd:ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001447362 ecd:YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember ecd:NonPeoNeoMember 2024-01-01 2024-12-31 0001447362 1 2024-01-01 2024-12-31 0001447362 2 2024-01-01 2024-12-31 0001447362 3 2024-01-01 2024-12-31 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No.___) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive Proxy Statement ☐ Definitive Additional Materials ☐ Soliciting Material under § 240.14a-12 CASTLE BIOSCIENCES, INC. (Name of Registrant as Specified In Its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ☒ No fee required ☐ Fee paid previously with preliminary materials ☐ Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11 Letter from our Chief Executive Officer April 9, 2025 DEAR FELLOW STOCKHOLDERS, I am pleased to invite you to Castle Biosciences’ 2025 Annual Meeting of Stockholders, being held Thursday, May 22, 2025, at 10 a.m. Central time. Our Annual Meeting offers a valuable opportunity to engage with you and seek your perspectives on matters important to Castle. The following Notice of Annual Meeting and accompanying Proxy Statement provide important details regarding the meeting. Our efforts over the past year have positively im

View on Read The Filing